Project Grant K01AG088489
Award Date 8/1/26
Completion Date 5/31/31
Dollars Obligated $101K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute on Aging awarded The University of Texas MD Anderson Cancer Center $451,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to model age-dependent HSP90 decline and genome instability in mammals. The project examines how heat shock protein 90 (HSP90), a sentinel of protein homeostasis, buffers deleterious mutations in critical DNA repair proteins FANCA and BRCA1, and investigates how HSP90's buffering capacity diminishes with age. The research uses...
- The National Institute on Aging awarded Texas Tech University $447,541 on February 1, 2026, under the Aging Research program (CFDA 93.866, assistance type: Project Grant) to investigate microRNA-driven mitochondrial dysfunction in Alzheimer's disease. The research focuses on validating microRNA PC-5P-12969 as both a biomarker for early Alzheimer's diagnosis and a potential therapeutic target. The recipient will measure microRNA PC-5P-12969 levels in blood, cerebrospinal fluid, and postmortem...
- The National Institute on Aging awarded The Medical University of South Carolina $443,940 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the link between Alzheimer's disease and improved anti-cancer immunity through regulation of mitochondrial ceramide metabolism in T-cells. The research tests the hypothesis that amyloid precursor protein and amyloid-beta peptides accumulate in T-cell mitochondria of aging patients with Alzheimer's disease, inhibiting...
- The National Institute on Aging awarded the University of Texas Health Science Center at Houston $1,308,220 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate epigenetic modulation by Enhancer of Zeste Homolog 2 (EZH2) in cerebral amyloid angiopathy and Alzheimer's disease. The research examines how EZH2, a master epigenetic modifier, controls endothelial nitric oxide synthase (eNOS) and claudin-5 tight-junction protein expression in cerebral vasculature. The...
- The National Heart, Lung and Blood Institute awarded The University of Texas MD Anderson Cancer Center $2,448,603 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms by which telomere damage compromises hematopoietic stem cell function and to uncover therapeutic strategies to ameliorate bone marrow failure disorders. The research dissects how progressive telomere shortening, which occurs over the human lifespan, drives...
- The National Institute on Aging awarded the University of Texas Medical Branch at Galveston $1.788 million on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the interplay between microglia and tau oligomer polymorphs in cognitive resilience among individuals with Alzheimer's disease neuropathology who remain cognitively intact. The project tests the hypothesis that brain-derived tau oligomers isolated from cognitively resilient individuals exhibit reduced toxicity...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded The University of Texas Southwestern Medical Center $249,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate an innovative genetic platform for de-risking g-secretase modulator therapeutics in Alzheimer's disease. The award funds two primary aims. Aim 1 involves using CRISPR/Cas9 engineering and structure-informed design to generate and validate a novel...
- The National Institute on Aging awarded The University of Texas MD Anderson Cancer Center $628,988 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate a nonhuman primate research infrastructure for studying female aging and perimenopause. The award funds development of a comprehensive baboon research infrastructure anchored at the Keeling Center for Comparative Medicine and Research. In the R61 phase, the recipient will assess feasibility and validity...
- The National Institute on Aging awarded the Regents of the University of Michigan $126,969 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research determining the unique molecular and cellular features of limbic-predominant age-related TDP-43 encephalopathy (LATE). The recipient will compare the intrinsic properties of TDP-43 aggregates in FTLD-TDP (frontotemporal lobar degeneration with TDP-43 deposition) and LATE through high-resolution cryo-electron microscopy...
- The National Institute on Aging awarded Dana-Farber Cancer Institute, Inc. $737,261 on July 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the functional consequences of germline-encoded telomere dysfunction and its role in age-related disease. The award funds research applying functional genomics to elucidate how rare variants in telomere maintenance genes affect telomere length and drive age-related cellular dysfunction and disease. The study combines genetic approaches...